BRAIN Biotech Valuation
Is 0RFI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0RFI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 0RFI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 0RFI's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0RFI?
Key metric: As 0RFI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0RFI's PS Ratio? | |
|---|---|
| PS Ratio | 1.2x |
| Sales | €56.26m |
| Market Cap | €68.82m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1x |
| Enterprise Value/EBITDA | -24.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0RFI's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
IOF Iofina | 0.9x | 9.8% | UK£36.5m |
CAR Carclo | 0.2x | 7.0% | UK£23.9m |
TET Treatt | 1.8x | 7.2% | UK£255.9m |
SYNT Synthomer | 0.1x | 5.0% | UK£268.2m |
0RFI BRAIN Biotech | 1.2x | 8.5% | €68.8m |
Price-To-Sales vs Peers: 0RFI is expensive based on its Price-To-Sales Ratio (1.2x) compared to the peer average (0.7x).
Price to Sales Ratio vs Industry
How does 0RFI's PS Ratio compare vs other companies in the GB Chemicals Industry?
Price-To-Sales vs Industry: 0RFI is expensive based on its Price-To-Sales Ratio (1.2x) compared to the UK Chemicals industry average (1.2x).
Price to Sales Ratio vs Fair Ratio
What is 0RFI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0RFI's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €3.25 | €6.30 +93.8% | 35.4% | €10.00 | €4.10 | n/a | 4 |
| Nov ’25 | €2.72 | €8.48 +211.6% | 52.0% | €15.00 | €4.10 | n/a | 4 |
| Oct ’25 | €2.03 | €8.48 +317.5% | 52.0% | €15.00 | €4.10 | n/a | 4 |
| Sep ’25 | €1.70 | €8.38 +392.6% | 53.6% | €15.00 | €4.10 | n/a | 4 |
| Aug ’25 | €2.00 | €10.50 +425.0% | 38.0% | €15.00 | €4.10 | n/a | 4 |
| Jul ’25 | n/a | €10.50 0% | 38.0% | €15.00 | €4.10 | n/a | 4 |
| Jun ’25 | n/a | €10.98 0% | 37.5% | €15.00 | €4.10 | n/a | 4 |
| May ’25 | €2.80 | €10.98 +292.0% | 37.5% | €15.00 | €4.10 | n/a | 4 |
| Apr ’25 | n/a | €10.98 0% | 37.5% | €15.00 | €4.10 | n/a | 4 |
| Mar ’25 | n/a | €11.23 0% | 33.0% | €15.00 | €5.10 | n/a | 4 |
| Feb ’25 | n/a | €11.23 0% | 33.0% | €15.00 | €5.10 | n/a | 4 |
| Jan ’25 | n/a | €11.23 0% | 33.0% | €15.00 | €5.10 | n/a | 4 |
| Dec ’24 | n/a | €11.23 0% | 33.0% | €15.00 | €5.10 | n/a | 4 |
| Nov ’24 | n/a | €11.23 0% | 33.0% | €15.00 | €5.10 | €2.72 | 4 |
| Oct ’24 | n/a | €11.23 0% | 33.0% | €15.00 | €5.10 | €2.03 | 4 |
| Sep ’24 | n/a | €11.23 0% | 33.0% | €15.00 | €5.10 | €1.70 | 4 |
| Aug ’24 | n/a | €12.23 0% | 26.6% | €15.00 | €7.00 | €2.00 | 4 |
| Jul ’24 | €4.17 | €12.23 +193.2% | 26.6% | €15.00 | €7.00 | n/a | 4 |
| Jun ’24 | n/a | €12.25 0% | 26.7% | €15.00 | €7.00 | n/a | 4 |
| May ’24 | €5.90 | €12.25 +107.6% | 26.7% | €15.00 | €7.00 | €2.80 | 4 |
| Apr ’24 | €5.66 | €12.25 +116.4% | 26.7% | €15.00 | €7.00 | n/a | 4 |
| Mar ’24 | n/a | €12.25 0% | 26.7% | €15.00 | €7.00 | n/a | 4 |
| Feb ’24 | n/a | €12.25 0% | 26.7% | €15.00 | €7.00 | n/a | 4 |
| Jan ’24 | n/a | €12.91 0% | 43.1% | €20.00 | €4.65 | n/a | 4 |
| Dec ’23 | n/a | €12.91 0% | 43.1% | €20.00 | €4.65 | n/a | 4 |
| Nov ’23 | n/a | €12.91 0% | 43.1% | €20.00 | €4.65 | n/a | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Zignago Vetro
€861.8m
Engages in the production, marketing, and sale of hollow glass containers in Italy, rest of Europe, and internationally.
0NNC
€9.58
7D
-2.5%
1Y
-24.6%
Altri SGPS
€1.0b
Produces and sells cellulosic fibers and energy in Portugal and internationally.
0DJV
€5.00
7D
-3.5%
1Y
4.4%
TFF Group
€687.3m
Manufactures and distributes barrels and wood products for the aging of wines and alcohols in France, rest of Europe, the United States, Asia, and internationally.
0IH4
€31.20
7D
-1.0%
1Y
-25.5%